MarketPulse
N

$NBTX

2 articles found
1 positive
0 negative
1 neutral
BenzingaBenzinga··Vandana Singh

Nanobiotix Shoots Down J&J Acquisition Rumors, Stock Soars on Clarity

Nanobiotix denies J&J acquisition rumors, shares rise 6.17%. Stock up 774.83% annually; reaffirms focus on advancing cancer pipeline, NBTXR3 partnership.
JNJNBTXcancer treatmentbiotechnology
BenzingaBenzinga··Benzinga

NBTX Denies Acquisition Speculation, Refutes Media Claims

Nanobiotix denies acquisition speculation, stating no acquisition intent or assessment underway. Company cites factual inaccuracies in media reports.
NBTXbiotechnologyoncology